Skip to Content

Corifact Approval History

FDA Approved: Yes (First approved February 17, 2011)
Brand name: Corifact
Generic name: factor XIII concentrate (human)
Company: CSL Behring LLC
Treatment for: Factor XIII Deficiency

Corifact (factor XIII concentrate (human)) is a is a fibrin-stabilizing factor concentrate indicated to prevent bleeding in people with congenital Factor XIII deficiency.

Development History and FDA Approval Process for Corifact

DateArticle
Feb 17, 2011Approval FDA Approves Corifact to Prevent Bleeding in People With Rare Genetic Defect

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide